Taxanes as adjuvant therapy for breast cancer

References

• Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 1998;352:930–942.
   Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365: 1687–1717.
   Google Scholar
• Bonadonna G, Valagussa P, Moliterni A, Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. New Engl J Med 1995;332:902–906.
   Google Scholar
• Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:483–496.
   Google Scholar
• Martin M, Villar A, Sol-e-Calco A, et al. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1,21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF, day 1,21) adjuvant chemotehrapy for operable breast cancer: a study by the GEICAM group. Ann Oncol 2003;14: 833–842.
   Google Scholar
• Fumoleau P, Kerbrat P, Romestaing P, et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 2003;21:298–305.
   PubMed Web of Science ®Google Scholar
• Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976–983.
   PubMed Web of Science ®Google Scholar
• Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effect in a dose-finding and sequence-finding study. J Clin Oncol 1995;13:2688–2699.
   PubMed Web of Science ®Google Scholar
• Gehl J, Boesgaanl M, Paaske T, et al. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic. Ann Oncol 1996:687–693.
   Google Scholar
• Mamounas EP, Bryant J, Lembersky BC, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP-B 28. J Clin Oncol 2005; 23:3686–3696.
   PubMed Web of Science ®Google Scholar
• Martin M, Rodriguez-Lescure A, Ruiz A, et al. Multicenter, randomized phase III study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FE90C versus 4 cyccles of FE90C followed by 8 weekly paclitaxel administrations: interim efficacy analy-sis of GEICAM 9906 trial. Breast Cancer Res Treat 2005; 94 (suppl 1):520 (abstract 39).
   Google Scholar
• Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302–2313.
   PubMed Web of Science ®Google Scholar
• Goldstein LJ, O'Neill A, Sparano JA, et al. E2197: Phase III of AT vs AC in the adjuvant treatment of node-positive and high-risk node-negative breast cancer. Proc Am Soc Clin Oncol 2005;24 (abstract 512).
   Google Scholar
• Roche H, Fumoleau P, Spielmann M, et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC 100 vs 3 cycles of FEC 100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node-positive breast cancer. Breast Cancer Res Treat 2004;88: (Abstract 27).
   Google Scholar
• Jones SE, Savin MA, Holmes FA et al. Final andlisis: TC (docetaxel/cyclophosphamide), 4 cycles) has a sup-erior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer. Breast Cancer Res Treat (2005; 94\(suppl 1):520 (abstract 40).
   Google Scholar
• Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431–1439.
   PubMed Web of Science ®Google Scholar
• Norton L. Kinetic concepts in the systemic drug therapy of breast cancer. Semin Oncol 1999;26:11–20.
   PubMedGoogle Scholar
• Sparano JA, Wang M, Martino S, et al. Phase III study of doxorubicin-cyclophosphanide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer. Results of North American Breast Cancer Intergroup Trial E1199. San Antonio Breast Cancer Symposium; 2005.
   Google Scholar
• Romond EH, Perez EP, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable her2- positive breast cncer. N Engl J Med 2005353:1673-1684.
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in her2-positive breast cancer. N Engl J Med 2005;353: 1659–1672.
   Google Scholar
• Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemothera-peutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241–2251.
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclopho-sphamide followed by docetaxel (AC —> T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC —> TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium; 2005.
   Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354: 809–820.
   PubMed Web of Science ®Google Scholar
• Martin M, Lluch A, Segui MA, et al. Toxicity and health-related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC (5-fluorouracil, doxorubicin, cyclophosphamide): impact of adding prophylactic growth factors to TAC. GEICAM study 9805. Proc Am Soc Clin Oncol 2005;29 (abstract 604).
   Google Scholar
• Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295:1658–1667.
   PubMed Web of Science ®Google Scholar